A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat
References (57)
- et al.
Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
Toxicol. Appl. Pharmacol.
(1987) - et al.
Methotrexate pharmacokinetics
J. Pharm. Sci.
(1971) - et al.
The metabolism of nicotine into two optically-active sterioisomers of nicotine-1′-oxide by animal tissues in vitro and by cigarette smokers
Biochem. Pharmacol.
(1970) - et al.
Enzymatic oxidation of (−)-nicotine by guinea-pig tissues in vitro
Biochem. Pharmacol.
(1971) - et al.
Physiologically based pharmacokinetic and pharmacodynamic model for inhibition of acetylcholinesterase by diisopropylfluorophosphate
Toxicol. Appl. Pharmacol.
(1990) - et al.
The metabolism of tobacco alkaloids
Essays Toxicol.
(1975) - et al.
Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex
Brain Res.
(1987) - et al.
A radiometric-high performance liquid chromatographic assay for nicotine and twelve metabolites
J. Chromatogr.
(1987) - et al.
A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-teterachlorodibenzo-p-dioxin in the rat
Toxicol. Appl. Pharmacol.
(1990) - et al.
Characterization of hamster liver nicotine metabolism. I. Relative rates of microsomal C and N oxidation
Biochem. Pharmacol.
(1986)
A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans
Toxicol. Appl. Pharmacol.
In vitro metabolism of methylene chloride in human and animal tissues: Use in physiologically based pharmacokinetic model
Toxicol. Appl. Pharmacol.
Pharmacokinetics of nicotine in rats after single-cigarette smoke inhalation
J. Pharm. Sci.
Mathematical modelling of nicotine and cotinine as biological markers of environmental tobacco smoke exposure
Toxicol. Lett.
Actions of nicotine and smoking on circulation
Pharmacol. Ther.
Toxicol. Appl. Pharmacol.
Disposition of nicotine in the rat after intravenous administration
Res. Commun. Chem. Pathol. Pharmacol.
Gastric excretion of C14-nicotine
Experimentia
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man
J. Pharmacol. Exp. Ther.
Nicotine renal excretion rate influences nicotine intake during cigarette smoking
J. Pharmacol. Exp. Ther.
The human pharmacology of nicotine
Res. Adv. Alcohol Drug Prob.
Pharmacokinetics, metabolism, and pharmacodynamics of nicotine
Stable isotope studies of nicotine kinetics and bioavailability
Clin. Pharmacol. Ther.
Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers
Drug Metab. Dispos.
Cigarette smoking in the United States, 1986
Morbidity Mortality Weekly Rep.
Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models
J. Pharmacokinet. Biopharm.
The central pharmacology of nicotine: electrophysiological approaches
A physiologically based pharmacokinetic model for nicotine in the rat
Toxicologist
Cited by (72)
Deconvolution of Systemic Pharmacokinetics Predicts Inhaled Aerosol Dosimetry of Nicotine
2023, European Journal of Pharmaceutical SciencesCitation Excerpt :Our PBPK model also predicted longer nicotine terminal elimination half-life due to the slow release of nicotine from lysosomes back into the systemic circulation. However, nicotine is also known to bind to receptors, and earlier PBPK models developed for different routes of administration have incorporated receptor binding to predict tissue distribution (Plowchalk et al., 1992; Robinson et al., 2005; Rostami et al., 2022; Teeguarden et al., 2013; Yang et al., 2020). These PBPK models were able to capture the rapid clearance of high systemic nicotine concentrations in different species but were unable to describe the terminal plasma nicotine concentrations (Yang et al., 2020).
Application of open-source PBPK models in rat-to-human pharmacokinetic extrapolation of oral nicotine exposure
2021, Computational ToxicologyUse of a physiologically-based pharmacokinetic model to explore the potential disparity in nicotine disposition between adult and adolescent nonhuman primates
2020, Toxicology and Applied PharmacologyCitation Excerpt :Thus, age-dependent changes for nicotine pharmacokinetics between human adults and youth warrant further evaluation. A number of PBPK models have been developed to describe the pharmacokinetics of nicotine and cotinine in rats (Plowchalk et al., 1992; Teeguarden et al., 2013; Saylor and Zhang, 2016) and humans (Robinson et al., 1992; Clewell et al., 2004; Yamazaki et al., 2010; Teeguarden et al., 2013; Gajewska et al., 2014; Saylor and Zhang, 2016), which focused primarily on adults. In addition to evaluating the kinetics of nicotine and cotinine across different exposure pathways, the model developed by Saylor et al. investigated the effect of anti-nicotine antibody on nicotine disposition in the brain with the description of antibody association and disassociation with nicotine (Saylor and Zhang, 2016).
Modelling ecological and human exposure to POPs in Venice lagoon – Part II: Quantitative uncertainty and sensitivity analysis in coupled exposure models
2016, Science of the Total EnvironmentA simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans
2016, Toxicology and Applied Pharmacology